Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia A Beaver

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
The New England Journal of Medicine|December 15, 2021
The Wild West of Checkpoint Inhibitor DevelopmentJulia A Beaver, Richard Pazdur
The New England Journal of Medicine|April 21, 2021
"Dangling" Accelerated Approvals in OncologyJulia A Beaver, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2015
Detecting Plasma Tumor DNA in Early-Stage Breast Cancer--ReplyJulia A Beaver, Ben Ho Park
Future Oncology (London, England)|July 7, 2012
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancerJulia A Beaver, Ben H Park
The New England Journal of Medicine|April 20, 2017
Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology TrialsJulia A Beaver, Gwynn Ison, Richard Pazdur
JAMA Oncology|October 28, 2021
Immunotherapy for Patients With Small-Cell Lung Cancer-2 Gains, 2 LossesHarpreet Singh, Julia A Beaver, Richard Pazdur
JAMA Oncology|May 5, 2022
Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score-ReplyChana Weinstock, Anup Amatya, Julia A Beaver
JAMA Oncology|April 15, 2021
Evaluating Cancer Drugs in Patients With Central Nervous System MetastasesShanthi Marur, Julia A Beaver, Richard Pazdur
JAMA Oncology|February 17, 2022
Reexamination of Patient Autonomy and Prior Therapies in Oncology Clinical Trial Eligibility CriteriaJennifer J Gao, Richard Pazdur, Julia A Beaver
The New England Journal of Medicine|February 15, 2019
Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast CancerTatiana M Prowell, Julia A Beaver, Richard Pazdur
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|December 15, 2021
The Wild West of Checkpoint Inhibitor DevelopmentJulia A Beaver, Richard Pazdur
The New England Journal of Medicine|April 21, 2021
"Dangling" Accelerated Approvals in OncologyJulia A Beaver, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2015
Detecting Plasma Tumor DNA in Early-Stage Breast Cancer--ReplyJulia A Beaver, Ben Ho Park
Future Oncology (London, England)|July 7, 2012
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancerJulia A Beaver, Ben H Park
The New England Journal of Medicine|April 20, 2017
Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology TrialsJulia A Beaver, Gwynn Ison, Richard Pazdur
JAMA Oncology|October 28, 2021
Immunotherapy for Patients With Small-Cell Lung Cancer-2 Gains, 2 LossesHarpreet Singh, Julia A Beaver, Richard Pazdur
JAMA Oncology|May 5, 2022
Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score-ReplyChana Weinstock, Anup Amatya, Julia A Beaver
JAMA Oncology|April 15, 2021
Evaluating Cancer Drugs in Patients With Central Nervous System MetastasesShanthi Marur, Julia A Beaver, Richard Pazdur
JAMA Oncology|February 17, 2022
Reexamination of Patient Autonomy and Prior Therapies in Oncology Clinical Trial Eligibility CriteriaJennifer J Gao, Richard Pazdur, Julia A Beaver
The New England Journal of Medicine|February 15, 2019
Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast CancerTatiana M Prowell, Julia A Beaver, Richard Pazdur
Pageof 15